Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for evidence in the transcript. The transcript covers Kamada's Q2 2023 earnings call. Management discusses various products: KEDRAB, CYTOGAM, HEPAGAMB, VARIZIG, WINRHO, and the InnovAATe trial. Also mentions plasma collection centers. Key points: - KEDRAB sales increased significantly. They mention "significant increase in demand for the product in the U.S." and "anticipate even further momentum in the second half of the year." But is that about unit size? They talk about increased sales, but not about the size of individual orders or contracts. They mention that Kedrion extended the distribution agreement through March 2026. That's a longer duration, but is that an escalation of unit size? The agreement extension is about duration, not necessarily about larger orders per instance. They also mention "active discussion with Kedrion to potentially further expand the scope of our collaboration." That suggests potential broader scope, but it's not yet realized. Also, they talk about the U.S. market being $150 million annually, and they are taking market share. But that's about volume, not about individual deal size. - For the IgG products, they mention "continued growth of the new IgG product sales in the U.S., fueled by the ongoing marketing efforts as well as the expansion of ex-U.S. sales." Again, that's about volume. - For InnovAATe trial, they mention enrollment ramping, but that's a clinical trial, not a commercial deal. - For plasma collection, they mention opening a second center in Houston in early 2024. That's expansion of sites, but not necessarily that each site is bigger. - They also mention the $60 million financing from FIMI, which is a strategic investment, not a business deal of the same kind. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.